Kautilya

Reliance Jio and Bharti Airtel Kick off 5G Network Trials in India

The Department of Telecommunications had in May allocated 5G trial spectrum in 700-megahertz (MHz), 3.2-3.6-gigahertz (GHz), and 24.25-28.5-GHz bands to Airtel, Jio, and Vodafone Idea to develop India-specific use-cases. Jio is using standalone 5G architecture for its trials and this will include testing of core and radio network for peak speed, latency, and data loads, said a source.

Raksha Mantri Calls for Open & Inclusive Order in Indo-Pacific at the 8th ASEAN Defence Ministers Meeting Plus

“India has strengthened its cooperative engagements in the Indo-Pacific based on converging visions and values for promotion of peace, stability and prosperity in the region. Premised upon the centrality of ASEAN, India supports utilisation of ASEAN-led mechanisms as important platforms for implementation of our shared vision for the Indo-Pacific,” he added.

Cabinet Approves Deep Ocean Mission

The Cabinet Committee on Economic Affairs chaired by Prime Minister Shri Narendra Modi, has approved the proposal of Ministry of Earth Sciences (MoES) on “Deep Ocean Mission”, with a view to explore deep ocean for resources and develop deep sea technologies for sustainable use of ocean resources.

New Precision Iodine Value Analyzer Gets Recognition by FSSAI

In one of its initiatives to encourage the manufacturing industry in India, CSIR-Central Scientific Instruments Organisation (CSIO) had developed and transferred the technology of “Precision Iodine Value Analyzer (PIVA)”, an instrument for the measurement of the degree of unsaturation (Iodine Value) in vegetable oils. This indigenous food testing equipment – PIVA was recognized by FSSAI during World Food Safety Day.

Novavax Set for India Launch with Serum Institute as Manufacturing Partner

The Novavax trials conducted on 29,960 people in the US and Mexico have delivered results that equal the Pfizer and Moderna jabs and do better than Johnson and Johnson, but regulatory clearance appears distant as an overflowing vault of vaccines has diminished the need for emergency use approvals. Additional EUAs are not required under US law after enough dosages are available to meet domestic demands.

Categories